Moderna fell in trading on Thursday after its vaccine revenues missed analysts’ expectations and the company made a small increase in product sales projections for the year.
While Moderna recorded its first profitable quarter, revenues of $1.94bn came in below Wall Street expectations. The 4.3% increase in projected annual product sales to $19.2bn pales in comparison to the $26bn that rival Pfizer now expects from Covid vaccine sales this year.
The final count depends on the mix of primary two-dose vaccine and booster shots that use less vaccine material.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: